![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to discover small molecule therapeutics against three undisclosed targets by using the power of artificial intelligence.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $1,237.5 million Upfront Cash: $37.5 million
Deal Type: Collaboration January 07, 2024
Details:
Under the terms of the agreement, Isomorphic Labs will collaborate with Lilly to discover small molecule therapeutics against multiple targets by using the power of artificial intelligence.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $1,745.0 million Upfront Cash: $45.0 million
Deal Type: Collaboration January 07, 2024